Financial Services Association, April 8 (Reporter He Fan) In the face of a decline in both total revenue and net profit in 2023, Wantai Biotech (603392.SH) was “troubled” by many investors during the pre-collection process, questioning the company's response plan when faced with pressure from overseas competition. Furthermore, there are endless questions about the company's senior business capabilities, such as the company's director, financial director, general manager, etc., about the focus of work. At the same time, the nine-valent and bivalent HPV vaccines are also topics that investors are very concerned about.

During the pre-collection Q&A session, Wantai Biotech “encountered” sharp questions from investors: “Jiadaxiu's nine-valent age extension has reduced the commercial value of the company's bivalent HPV vaccine to zero. Now MSD has not only applied for male indications, but has also begun clinical trials with a simplified dose. Does the company feel urgent pressure? Does the company have a solution?”

In response to this issue, the company said that clinical trials of the company's nine-valent HPV vaccine for men are being planned, and the advantages and sales strategies of the company's bivalent HPV vaccine were introduced in terms of both domestic and international sales.

Immediately after that, some investors questioned whether the company's new directors and secretaries answered investors' questions too infrequently on interactive platforms, and whether there was a situation where high salaries were low. In response, the company stated that it has always attached great importance to communication and communication with investors, and has not responded positively.

According to public information, the board of directors of the company appointed Yu Tao as the current director secretary on August 24, 2023, with a total salary of 1.094,200 yuan before tax.

However, the company's other executives have not been “spared”. Investors believe that the company's financial director is accurately reducing holdings at a high level and preparing to increase the price difference at a low level through equity incentives; however, securities agents are unable to effectively communicate with investors. They inquire whether they are considering moving the securities department to Xiamen or replacing the license generation?

Wantai Biotech responded that the company's executives made their own decisions to reduce their holdings based on individual financial needs, and that there is no inevitable link between the fairness and impartiality of the company's information disclosure and where the securities department is located.

Meanwhile, Jiang Zhiming, the general manager who only took office on January 16 this year, has also received much attention. Most of his past positions have focused on the fields of molecular diagnosis, life science, and clinical diagnosis, so investors are asking if the company will focus on IVD development in the future. General manager Jiang Zhiming (Jiang Zhiming) provided a reasonable response: “The company insists on collaborative development through vaccines and diagnostics.”

In the face of a sharp decline in performance, investors are very concerned about the progress of the company's nine-valent HPV vaccine. In the previous performance conference and interactive platform, the company stated that the on-site work for the phase V8 visit of its nine-valent HPV vaccine phase III main clinical trial has been completed and that specimen testing work is being carried out. Once cases of continuous infection have been accumulated that meet the mid-term declaration conditions, it will submit a marketing declaration as soon as possible. Also, the production workshop built for the company's nine-valent HPV vaccine has been completed, and process verification is ongoing.

Today, in response to related questions, the company's chairman Qiu Zixin said, “The marketing application for the nine-valent HPV vaccine is progressing according to plan.” Furthermore, it stated that “Phase III clinical trials of the nine-valent HPV vaccine are being carried out according to the plan.” However, as of the press release, the company had not answered questions about whether the process verification of the production workshop built by the company for this vaccine has been completed, production capacity plans, and peak expectations for the nine-valent HPV vaccine.

At the same time, the issue of the bivalent HPV vaccine has also drawn attention. The company said that the current stocks of the bivalent HPV vaccine are expected to be used up during the expiration date of the product.

It is worth noting that Wantai Biotech's bivalent HPV vaccine won the bid for 86 yuan/tube in Xiamen last month, with an astonishing price reduction of more than 50%. However, the Financial Services Association reporter asked whether the price reduction was an individual case or a general reduction and its impact on performance until the end of the performance, and the company did not respond to the above questions.

On the other hand, Qiu Zixin said that at present, the company and Health Hall have defined and divided the scope of business in the biomedical field, but it is not ruled out that the company will explore the possibility of incorporating the treatment sector into the listed company at the right time in the future.